Thus, inhibition or knockdown of SARM1 through use of pharmacological, gene therapy and antisense oligonucleotide approaches have become very attractive therapeutic strategies to trial in various neurological diseases (Geisler et al., 2019b; Coleman and Höke, 2020; Krauss et al., 2020; Arthur-Farraj and Coleman, 2021; Bosanac et al., 2021; Gould et al., 2021a; Merlini et al., 2022). This evidence concerns the gene SARM1 and nervous system disorder.